Advertisement

Medical Oncology and Tumor Pharmacotherapy

, Volume 6, Issue 4, pp 255–257 | Cite as

Buserelin treatment of advanced prostatic cancer: A phase II study

  • A. Veronesi
  • G. Lo Re
  • V. Dal Bo
  • M. D. Magri
  • M. Della Valentina
  • R. Talamini
  • A. Merlo
  • M. Francini
  • S. Monfardini
Original Articles
  • 22 Downloads

Abstract

From August 1986 to September 1988, 76 eligible patients with advanced prostatic carcinoma, measurable or evaluable disease, no previous hormonal treatment, were treated with Buserelin at a dosage of 500 μg every 8 h for 7 days, followed by 400 μg intranasally three times a day. No concomitant antiandrogens were administered. In the 63 evaluable patients (11 patients not yet evaluable because of short treatment time, two lost to follow-up), three complete remissions, 28 partial remissions, 30 stable disease and two progressions were obtained (National Prostatic Cancer Project criteria). Median duration of response was 55+ weeks. Side effects were modest, mostly related to the endocrinological effects of Buserelin. Transient increase in serum testosterone levels was found in 37% of the evaluable patients, but transitory ‘flare-up’ was present in seven patients only. With a median follow-up time of 11.5 months, median survival has not been reached. In conclusion, this study confirmed the activity of Buserelin and the feasibility of its middle-term administration.

Key words

Prostatic carcinoma Hormone treatment Buserelin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Byar D P: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate.Cancer 32, 1126 (1973).PubMedCrossRefGoogle Scholar
  2. 2.
    Mackintosh F R, Mackintosh C L, Hall S W: Toxicity of conventional hormonal therapy (CHT) for metastatic prostatic cancer (MPC).Proc ASCO 7, 123 (1988).Google Scholar
  3. 3.
    Eisenberger M A, O’Dwyer P J, Friedman M A: Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma.J clin Oncol 4, 414 (1986).PubMedGoogle Scholar
  4. 4.
    Falkson G, Vorobiof D: Intranasal Buserelin in the treatment of advanced prostatic cancer: a phase II trial.J clin Oncol 5, 1419 (1987).PubMedGoogle Scholar
  5. 5.
    Koutsilieris M, Tolis G: Long-term follow-up of patients with advanced prostatic carcinoma treated with either Buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome.The Prostate 7, 31 (1985).PubMedCrossRefGoogle Scholar
  6. 6.
    Schmidt J D, Scott W W, Gibbons R, Johnson D E, Prout G R Jr, Loening S, Soloway M, DeKernion J, Edson Pontes J, Slack N H, Murphy G P: Chemotherapy programs of the National Prostatic Cancer Project (NPCP).Cancer 45, 1937 (1980).PubMedGoogle Scholar
  7. 7.
    Benedetti J, Yean K, Young L:BMDP Statistical Software, pp. 557–575. Berkeley, University of California Press (1983).Google Scholar
  8. 8.
    Presant C A, Soloway M S, Klioze S S, Yakabow A, Presant S N, Mendez R G, Kennedy P S, Wyrs M R, Naessig V L, Todd B, Wiseman C L, Bouzaglou A, Tanenbaum B, Eventov D: Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life.Cancer 59, 1713 (1987).PubMedCrossRefGoogle Scholar
  9. 9.
    Waxman J H, Sandow J, Man A, Barnett M J, Hendry W F, Besser G M, Oliver R T D, Magill I J: The first use of depot Buserelin for advanced prostatic carcinoma.Cancer Chemother Pharmac 18, 174 (1986).Google Scholar
  10. 10.
    The Leuprolide Study Group: Leuprolide versus Diethylstilbestrol for metastatic prostate cancer.New Engl J Med 311, 1281 (1984).CrossRefGoogle Scholar
  11. 11.
    Vogelzang N, Citrin D, Chodak G, Anderson T, Lawrence H J, Scott M, Gau T for the Zoladex prostate study group: Phase III randomized trials of depot Zoladex and standard hormonal therapy in advanced prostate cancer.Proc ASCO 7, 119 (1988).Google Scholar

Copyright information

© Humana Press Inc. 1989

Authors and Affiliations

  • A. Veronesi
    • 1
  • G. Lo Re
    • 1
  • V. Dal Bo
    • 3
  • M. D. Magri
    • 1
  • M. Della Valentina
    • 1
  • R. Talamini
    • 2
  • A. Merlo
    • 3
  • M. Francini
    • 3
  • S. Monfardini
    • 1
  1. 1.Division of Medical OncologyCentro di Riferimento OncologicoAviano
  2. 2.Epidemiology UnitCentro di Riferimento OncologicoAviano
  3. 3.Division of UrologyGeneral HospitalPordenoneItaly

Personalised recommendations